SlideShare a Scribd company logo
GROUP PROJECT PRESENTATION
PRESENTED BY
LEARNING GROUP 16
HUMAN WELFARE
GROUPS
TO COMAPARE THE SAFETY & EFFICACY OF TWO DIFFERENT
DOTS REGIMEN IN HIV +ve AND NON HIV PATIENTS, INFECTED
WITH TUBERCULOSIS
A Multicentre Phase III Open-Label Study
PROJECT OBJECTIVE
• To conduct market research for selection of
potential site and feasibility of carrying out the
trial in those sites.
• To develop all trial related ethical submission
deliverables.
• To prepare the budget for carrying out the trial.
• To develop SOPs for all trial related activities.
TASK DELEGATION
NAME OF THE PERSON ROLES RESPONSIBILITIES
SUBENDU MUKHERJEE PROJECT MANAGER PROTOCOL, RMP,
MEETING AGENDA’S,
SYSTEMATIC REVIEW
SARAH TAREEN DEPUTY PROJECT
MANAGER
IB, LITERATURE SEARCH
, SYSTEMATIC REVIEW
P.SHEELA CLINICAL OPERATION
MANAGER
CRF, QOL, REGULATORY
REQUIREMENTS.
PANKAJA GOHAIN ADMINISTRATIVE &
OPERATION CO-
ORDINATOR
ICF, MEDICAL
INSURANCE, SITE
FEASIBILITY CHECKLIST,
RECORDING MINUTES
OF MEETING
SUNITA KUMARI FINANCIAL PLANNER CONFIDENTIALITY
REPORT, RMP,BUDGET,
SLIDES
A.MADHURI QUALITY CONTROL &
QUALITY ASSURANCE
MANAGER
SOP’s, PRESENTATION
DAY CO-
ORDINATOR,POSTER.
Management plan
• Adherence to Team SOP’s
• Weekly project team status reports
• Summary of tasks completed in the previous week
• Summary of tasks scheduled for completion in the next week
• Compliance with the communication plan and Delegation plan
• Monitoring and tracking individual work
• Meeting with sponsors and reporting project progress in
periodic basis.
PROPOSAL STRATEGY
• Detailed literature search was done for selecting appropriate site;
sites were to be personally visited.
• Sites were to be reviewed via site selection checklist.
• Trial related essential documents were to be submitted as per
Indian GCP.
• Standard cost criteria were to be adopted for the budget.
• SOPs were to be developed in accordance with applicable
regulatory requirements, sponsor’s demands and company
standards.
PROJECT SCHEDULE
• Gantt Chart
• group projectProject1-GANTT CHART.mpp
BACKGROUND OF THE PROJECT
• In last two years 1.8 million cases of TB have been reported in
India.
• 2009 figure says, there are 2.5 million people suffering from HIV
in India.
• 26% of the cause for death in HIV infected patients is due to TB.
• No trial in India has been conducted yet.
• 95% cases of TB are reported in South India and Maharashtra
• Number of deaths per year is next to cancer and cardiac
diseases.
BENEFITS OF THE STUDY
• Will walkout with better health conditions..
• Study will enrich their quality of life
• Will be exposed to the best treatment to
tackle their health hazards.
Individual-
wise
• Help reduce mortality rate for developing
countries like India
• Improve the QOL for people suffering with
TB
Society-
wise
• This trial can help come up with newer
findings for DOTS regimen as only a few
trial regarding this therapy have been
conducted.
Science-
wise
SPONSOR’S
DELIVERABLES
Protocol
IB
CRF
ICF
SOPs
Medical
Insurance
Site
Selection
Checklist
RMP
Confidenti-
ality
Agreement
Budget
Systematic
Review
QOL
Question-
naire
PROJECT
MANAGEMENT
DELIVERABLES
Agenda
Minutes of
meeting
Delegatio
n Report
Executive
Summary
Communication
Report
CRITICAL CONSTRAINTS
• No previous experience in such projects
• Tasks may take longer time than expected
• Absenteeism of group member
• Loss of data
• Delay in work due to power cuts
PROTOCOL
• AIM : :
COMAPARE THE SAFETY & EFFICACY OF TWO DIFFERENT DOTS
REGIMEN IN HIV +ve AND NON HIV PATIENTS, INFECTED WITH
TUBERCULOSIS
• OBJECTIVE:
 PRIMARY: To compare the efficacy parameters of two different DOTS
regimen in HIV and non HIV patients, in treating tuberculosis.
 SECONDARY :
1. To determine the Frequency of ADR in each group of population
2. To determine the survival rate
3. To assess the quality of life of both the population
PROTOCOL CONTD.
• Study Design: Phase III, non-randomized, open -label, cross-over assignment,
multicentre.
• SETTINGS: BANGALORE, PUNE, CHENNAI, COCHIN, PUNE.
• SAMPLE : 9 0 0 subjects
• STUDY DURATION : 3 Years and 2 months.
• Primary Endpoints:
Reduction in mycobacterium infection in both groups, i.e., reduction in amount of
M.Tuberculli infection in sputum test, pulmonary tapping, chest x-ray
• Secondary Endpoints:
Number of ADR’s in both the groups will be collected and evaluated; number of
deaths in both the groups, periodic scores of WHO HIV tool quality of life
questionnaire will be assessed.
PROTOCOL CONTD.
• Safety Endpoint:
Occurrence of any ADR or SAE will be considered as safety endpoint.
• INCLUSION CRITERIA for HIV + ve + TB group:
i. Confirmed diagnosed HIV infection within last 2 years.
ii. Confirmed diagnosed TB infection – TB rapid test or sputum smear +ve for acid fast bacilli in last 2
years.
iii. Age > 18
iv. Both gender
v. Life expectancy of atleast 6 months.
vi. Should comply with all study procedures
vii. Should provide voluntary written informed consent.
Clinical parameters:
Neutrophill count > 0.75 * 109 /L
Platelet count > 50 * 109/L
Hb > 80g/L
CD4 + cells < 200 and > 80
PROTOCOL CONTD.
EFFICACY ASSESSMENT:
 1, 2,3,4th month under both the regimen for both the study groups .
 To check reduction in M. tuberculli infection from the baseline score.
 Via. Sputum test, pulmonary tapping.
 Chest X-ray – to check the reduction in cough.
 During follow-up along with the above parameters,
survival rate and quality of life by WHO standard HIV-TB tool questionnaire will be
assessed.
• SAFETY ASSESSMENT:
• Routine safety assessment test include various test like, physical examination and vital
stats parameters. Clinical lab values of CD4 cell count. Reports of any adverse events
throughout the trial of every individual subject will be considered for safety assessment.
STATISTICS
SYSTEMATIC LITERATURE REVIEW
• Comprehensive search of published article was done
• Clinical trials using rifampin, pyrazinamide, isoniazid
and rifabutin drug as investigational product were
selected
• Retrospective and prospective studies.
• No standard inclusion or exclusion criteria
• All possible databases were included- PUBMED,
NEJM, BMJ
• Keywords used for search: , tuberculosis and HIV,
DOTS regimen, treatment outcome with Rifampin,
Isoniazid, Pyrazinamide, rifabutin
INVESTIGATOR’S BROCHURE
• IB was prepared in accordance with the Indian GCP.
• IB included all the necessary information about the drugs used in the
study: Isoniazid, Rifampin, Rifabutin, Pyrazinamide.
• For the above mentioned drugs, along with a brief summary of each
drug, the following information was included:
• Chemical, Physical and formulation parameters.
• Data from nonclinical studies
• Data from clinical studies
• Post marketing experience of each drug
• Summary of data and guidance for the investigator
INFORMED CONSENT dOCUMENT
• PATIENT INFORMATION SHEET:
• Patients were formally invited for the trial
• They were informed about all the details of the trial
• Information about all the personnel involved in the trial
• INFORMED CONSENT FORM:
• A document containing all the terms and conditions related to the participation in the
trial-to be read and signed and dated by the participant or LAR.
• Investigator’s certificate declaring that the informed consent was read and signed by
the participant.
• ICF for TB in non-HIV final.doc
• ICF for TB+HIV final.doc
SITE SELECTION CKECKLIST
• Market research was done for selecting
potential site
• Telephonic interview was done with the
shortlisted sites
• F:SITE SELECTION CHECKLIST.docx
CASE REPORT FORM
• The following headings included all the
necessary information needed to be
recorded, as per the requirements of
the protocol:
• CASE REPORT FORM 2.docx
• QOL_Questionnare.docx
Risk management plan
 Risk to participants right
• Fully IC
• Failure to protect participants privacy
 Risk to participants safety
• Hazard of the trial medication
• Hazards of study assessment methods
 Risk to researchers
• Staff competence / experience to carry out responsibilities
• Contact with harmful chemicals, substances, equipment or organisms
• Trial proceeding without the necessary regulatory approvals
 RISKS TO COMPLETION OF THE TRIAL
• Study Power & Recruitment
• Organisational Complexity
• Adequacy of trial management
 RISKS TO RELIABILITY OF THE RESULTS
• Study result
• Completeness and accuracy of assessment / data
• Adherence to the protocol
 RISKS TO THE ORGANISATION
• Impact on clinical services
• Liability
Trial budget
Recurring budget-
• staff expenses , travel, food, lab cost = INR
3,49,67000
Non recurring-
• Med claim, IEC approval, RA, Recruitment, Site
cost , Logistics =INR 892000
Miscellaneous expenses = INR 2,35,000
SOPs
• SOP
• Audit
• Participant recruitment
• ICD
• SAE reporting plan
• Trial Master file checklist
• Monitoring plan
Close out to include a discussion of lessons learnt
• To work as a team
• Time management
• Quality work
• Effective communication
• Understand the importance of roles and
responsibilities
• Identify and overcome the constraints
BETTER
TREATMENT
BETTER
SUPPORT

More Related Content

What's hot

ICH GCP
ICH GCPICH GCP
regulatory perspectives of clinical trails
regulatory perspectives of clinical trails regulatory perspectives of clinical trails
regulatory perspectives of clinical trails
Pankaj Maurya
 
When Digital Meets Medical: The Next Generation Clinical Trial
When Digital Meets Medical: The Next Generation Clinical TrialWhen Digital Meets Medical: The Next Generation Clinical Trial
When Digital Meets Medical: The Next Generation Clinical Trial
Celine Pering
 
ICMR guidelines for IEC - an overview
ICMR  guidelines for IEC -  an overviewICMR  guidelines for IEC -  an overview
ICMR guidelines for IEC - an overview
sathyanarayanan varadarajan
 
ICH GCP guidelines
ICH GCP guidelinesICH GCP guidelines
ICH GCP guidelines
rx_sonali
 
Designing of clinical study documentation -protocol and crf
Designing of clinical study documentation -protocol and crfDesigning of clinical study documentation -protocol and crf
Designing of clinical study documentation -protocol and crf
Rumana Hameed
 
Cdrh learn module gcp 101 -lacorte
Cdrh learn module gcp 101 -lacorteCdrh learn module gcp 101 -lacorte
Cdrh learn module gcp 101 -lacortegy2139
 
Corporate Brochure (WEB)
Corporate Brochure (WEB)Corporate Brochure (WEB)
Corporate Brochure (WEB)Thomas Poirier
 
Ethical Considerations In Clinical Trials
Ethical  Considerations In  Clinical  TrialsEthical  Considerations In  Clinical  Trials
Ethical Considerations In Clinical Trialskrathishbopanna
 
IPF/ILD Working Group ERS 2017
IPF/ILD Working Group ERS 2017IPF/ILD Working Group ERS 2017
IPF/ILD Working Group ERS 2017
Kathryn Brown
 
First approach of mobile applications study for medical Education purposes
First approach of mobile applications study for medical Education purposesFirst approach of mobile applications study for medical Education purposes
First approach of mobile applications study for medical Education purposes
Technological Ecosystems for Enhancing Multiculturality
 
Good Clinical Practices
Good Clinical PracticesGood Clinical Practices
Good Clinical Practices
Karun Kumar
 
Origin and principles of international conference on harmonization- Good clin...
Origin and principles of international conference on harmonization- Good clin...Origin and principles of international conference on harmonization- Good clin...
Origin and principles of international conference on harmonization- Good clin...
AbhishekJoshi312
 
Clinical trial study team
Clinical trial study teamClinical trial study team
Clinical trial study team
ManjuJhakhar
 
Local Guidelines in Infection Prevention and Control
Local Guidelines in Infection Prevention and ControlLocal Guidelines in Infection Prevention and Control
Local Guidelines in Infection Prevention and Control
Philippine Hospital Infection Contol Nurses Associaton (PHICNA) Inc.
 
History ethical guide lines to clinical trial
History ethical guide lines to clinical trialHistory ethical guide lines to clinical trial
History ethical guide lines to clinical trial
Anju Thejkumar
 
Roles and Responsibilities of sponsor in conducting clinical trials as per GC...
Roles and Responsibilities of sponsor in conducting clinical trials as per GC...Roles and Responsibilities of sponsor in conducting clinical trials as per GC...
Roles and Responsibilities of sponsor in conducting clinical trials as per GC...
Dr B Naga Raju
 

What's hot (20)

ICH GCP
ICH GCPICH GCP
ICH GCP
 
regulatory perspectives of clinical trails
regulatory perspectives of clinical trails regulatory perspectives of clinical trails
regulatory perspectives of clinical trails
 
Web 2.0 In Clinical Research
Web 2.0 In Clinical ResearchWeb 2.0 In Clinical Research
Web 2.0 In Clinical Research
 
When Digital Meets Medical: The Next Generation Clinical Trial
When Digital Meets Medical: The Next Generation Clinical TrialWhen Digital Meets Medical: The Next Generation Clinical Trial
When Digital Meets Medical: The Next Generation Clinical Trial
 
ICMR guidelines for IEC - an overview
ICMR  guidelines for IEC -  an overviewICMR  guidelines for IEC -  an overview
ICMR guidelines for IEC - an overview
 
ICH GCP guidelines
ICH GCP guidelinesICH GCP guidelines
ICH GCP guidelines
 
Designing of clinical study documentation -protocol and crf
Designing of clinical study documentation -protocol and crfDesigning of clinical study documentation -protocol and crf
Designing of clinical study documentation -protocol and crf
 
Corporate Brochure (WEB)
Corporate Brochure (WEB)Corporate Brochure (WEB)
Corporate Brochure (WEB)
 
Cdrh learn module gcp 101 -lacorte
Cdrh learn module gcp 101 -lacorteCdrh learn module gcp 101 -lacorte
Cdrh learn module gcp 101 -lacorte
 
Corporate Brochure (WEB)
Corporate Brochure (WEB)Corporate Brochure (WEB)
Corporate Brochure (WEB)
 
Ethical Considerations In Clinical Trials
Ethical  Considerations In  Clinical  TrialsEthical  Considerations In  Clinical  Trials
Ethical Considerations In Clinical Trials
 
IPF/ILD Working Group ERS 2017
IPF/ILD Working Group ERS 2017IPF/ILD Working Group ERS 2017
IPF/ILD Working Group ERS 2017
 
First approach of mobile applications study for medical Education purposes
First approach of mobile applications study for medical Education purposesFirst approach of mobile applications study for medical Education purposes
First approach of mobile applications study for medical Education purposes
 
Good Clinical Practices
Good Clinical PracticesGood Clinical Practices
Good Clinical Practices
 
Origin and principles of international conference on harmonization- Good clin...
Origin and principles of international conference on harmonization- Good clin...Origin and principles of international conference on harmonization- Good clin...
Origin and principles of international conference on harmonization- Good clin...
 
Clinical trial study team
Clinical trial study teamClinical trial study team
Clinical trial study team
 
Local Guidelines in Infection Prevention and Control
Local Guidelines in Infection Prevention and ControlLocal Guidelines in Infection Prevention and Control
Local Guidelines in Infection Prevention and Control
 
History ethical guide lines to clinical trial
History ethical guide lines to clinical trialHistory ethical guide lines to clinical trial
History ethical guide lines to clinical trial
 
Roles and Responsibilities of sponsor in conducting clinical trials as per GC...
Roles and Responsibilities of sponsor in conducting clinical trials as per GC...Roles and Responsibilities of sponsor in conducting clinical trials as per GC...
Roles and Responsibilities of sponsor in conducting clinical trials as per GC...
 
Nurses No Harm
Nurses No HarmNurses No Harm
Nurses No Harm
 

Viewers also liked

Unelte pentru comunicare
Unelte pentru comunicareUnelte pentru comunicare
Unelte pentru comunicareRuxandra Popa
 
Bhutan rural construction-rules 2013
Bhutan rural construction-rules 2013Bhutan rural construction-rules 2013
Bhutan rural construction-rules 2013
Bhim Upadhyaya
 
Swmt 2010 organizatii
Swmt 2010 organizatiiSwmt 2010 organizatii
Swmt 2010 organizatiiRuxandra Popa
 
Kick off
Kick offKick off
Il futuro dei CSS è nel tuo browser
Il futuro dei CSS è nel tuo browserIl futuro dei CSS è nel tuo browser
Il futuro dei CSS è nel tuo browser
SkillsAndMore
 
Swh&pcn in new orleans 11 march2013
Swh&pcn in new orleans 11 march2013Swh&pcn in new orleans 11 march2013
Swh&pcn in new orleans 11 march2013Charles Figley
 
Hello, my name is, Tiffany Sacks
Hello, my name is, Tiffany SacksHello, my name is, Tiffany Sacks
Hello, my name is, Tiffany SacksTiffany
 
New Deck
New DeckNew Deck
New Deck
Chris Mitchell
 
Presentasi Testing & Implementasi Sistem 2012
Presentasi Testing & Implementasi Sistem 2012Presentasi Testing & Implementasi Sistem 2012
Presentasi Testing & Implementasi Sistem 2012Dion Webiaswara
 
Teatro 2012
Teatro 2012Teatro 2012
Teatro 2012
Anabel Lee
 
How to video embed
How to video embedHow to video embed
How to video embed
jwlutgendorff
 
Therapeutic comm
Therapeutic commTherapeutic comm
Therapeutic commJudy Arpaio
 
After the silence a film
After the silence a filmAfter the silence a film
After the silence a film
Chole Richard
 
Staff training
Staff trainingStaff training
Staff trainingGoDesi.com
 
Kebijakan pendataan dan panduan teknis penggunaan aplikasi dapodikmen
Kebijakan pendataan dan panduan teknis penggunaan aplikasi dapodikmenKebijakan pendataan dan panduan teknis penggunaan aplikasi dapodikmen
Kebijakan pendataan dan panduan teknis penggunaan aplikasi dapodikmenSMK Negeri 2 Tamiang Layang
 

Viewers also liked (20)

Unelte pentru comunicare
Unelte pentru comunicareUnelte pentru comunicare
Unelte pentru comunicare
 
Bhutan rural construction-rules 2013
Bhutan rural construction-rules 2013Bhutan rural construction-rules 2013
Bhutan rural construction-rules 2013
 
Souththailand
SouththailandSouththailand
Souththailand
 
Swmt 2010 organizatii
Swmt 2010 organizatiiSwmt 2010 organizatii
Swmt 2010 organizatii
 
Kick off
Kick offKick off
Kick off
 
Il futuro dei CSS è nel tuo browser
Il futuro dei CSS è nel tuo browserIl futuro dei CSS è nel tuo browser
Il futuro dei CSS è nel tuo browser
 
Swh&pcn in new orleans 11 march2013
Swh&pcn in new orleans 11 march2013Swh&pcn in new orleans 11 march2013
Swh&pcn in new orleans 11 march2013
 
Hello, my name is, Tiffany Sacks
Hello, my name is, Tiffany SacksHello, my name is, Tiffany Sacks
Hello, my name is, Tiffany Sacks
 
New Deck
New DeckNew Deck
New Deck
 
Presentasi Testing & Implementasi Sistem 2012
Presentasi Testing & Implementasi Sistem 2012Presentasi Testing & Implementasi Sistem 2012
Presentasi Testing & Implementasi Sistem 2012
 
Teatro 2012
Teatro 2012Teatro 2012
Teatro 2012
 
Ss
SsSs
Ss
 
How to video embed
How to video embedHow to video embed
How to video embed
 
Therapeutic comm
Therapeutic commTherapeutic comm
Therapeutic comm
 
Coffee
CoffeeCoffee
Coffee
 
After the silence a film
After the silence a filmAfter the silence a film
After the silence a film
 
Cloth lesson
Cloth lessonCloth lesson
Cloth lesson
 
Periodic table
Periodic tablePeriodic table
Periodic table
 
Staff training
Staff trainingStaff training
Staff training
 
Kebijakan pendataan dan panduan teknis penggunaan aplikasi dapodikmen
Kebijakan pendataan dan panduan teknis penggunaan aplikasi dapodikmenKebijakan pendataan dan panduan teknis penggunaan aplikasi dapodikmen
Kebijakan pendataan dan panduan teknis penggunaan aplikasi dapodikmen
 

Similar to Effects of dots in HIV infected patients suffering from Tuberculosis

Introduction to Phase 2 & 3 Clinical Trials
Introduction to Phase 2 & 3 Clinical TrialsIntroduction to Phase 2 & 3 Clinical Trials
Introduction to Phase 2 & 3 Clinical Trials
Institute for Clinical Research (ICR)
 
Presentation on theme: "GCP (GOOD CLINICAL PRACTISE)"
Presentation on theme: "GCP (GOOD CLINICAL PRACTISE)"Presentation on theme: "GCP (GOOD CLINICAL PRACTISE)"
Presentation on theme: "GCP (GOOD CLINICAL PRACTISE)"
Nevin Francis
 
clinial trail documentation ppt M pharm pharmacology
clinial trail documentation ppt M pharm pharmacologyclinial trail documentation ppt M pharm pharmacology
clinial trail documentation ppt M pharm pharmacology
Mansi Nikhade
 
New Drug Discovery.pptx
New Drug Discovery.pptxNew Drug Discovery.pptx
New Drug Discovery.pptx
Dr. Bijoy Bakal
 
planning and initiation.pptx
planning and initiation.pptxplanning and initiation.pptx
planning and initiation.pptx
seeja2
 
Drug trail in cardiology i.tammi raju
Drug trail in cardiology i.tammi rajuDrug trail in cardiology i.tammi raju
Drug trail in cardiology i.tammi rajuTammiraju Iragavarapu
 
ROLES AND RESPONSIBLITIES OF CLINICAL TRIAL PERSONNEL-INVESTIGATOR.pptx
ROLES AND RESPONSIBLITIES OF CLINICAL TRIAL PERSONNEL-INVESTIGATOR.pptxROLES AND RESPONSIBLITIES OF CLINICAL TRIAL PERSONNEL-INVESTIGATOR.pptx
ROLES AND RESPONSIBLITIES OF CLINICAL TRIAL PERSONNEL-INVESTIGATOR.pptx
E Poovarasan
 
Clinical trials
Clinical trialsClinical trials
Clinical trials
SnehashisSarkar4
 
DEVELOPING CLINICAL TRIAL PROTOCOL BY PRANAV LENDHEY.pptx
DEVELOPING CLINICAL TRIAL PROTOCOL BY PRANAV LENDHEY.pptxDEVELOPING CLINICAL TRIAL PROTOCOL BY PRANAV LENDHEY.pptx
DEVELOPING CLINICAL TRIAL PROTOCOL BY PRANAV LENDHEY.pptx
36PranavLendhey
 
bharat seminar on clinical trial.pptx
bharat  seminar on clinical trial.pptxbharat  seminar on clinical trial.pptx
bharat seminar on clinical trial.pptx
DrxParmeshwarTurePat
 
Clinical trial study team
Clinical trial study teamClinical trial study team
Clinical trial study team
BharatPatil42
 
CRO.pptx
CRO.pptxCRO.pptx
Cinical trial protocol writing
Cinical trial protocol writingCinical trial protocol writing
Cinical trial protocol writing
Urmila Aswar
 
institutional ethics committee
institutional ethics committeeinstitutional ethics committee
institutional ethics committee
Sirisha Annavarapu
 
Preparation of protocol
Preparation of protocolPreparation of protocol
Preparation of protocol
RushikeshTidake
 
Turacoz - Clinical Study Report
Turacoz - Clinical Study ReportTuracoz - Clinical Study Report
Turacoz - Clinical Study Report
Turacoz Healthcare Solutions
 
What is clinical research? Why to do it?
What is clinical research? Why to do it?What is clinical research? Why to do it?
What is clinical research? Why to do it?
vsharma1087
 
signaldetectionandmanagement-210803014643.pdf
signaldetectionandmanagement-210803014643.pdfsignaldetectionandmanagement-210803014643.pdf
signaldetectionandmanagement-210803014643.pdf
dabloosaha
 
Signal detection and management
Signal detection and managementSignal detection and management
Signal detection and management
sekharbabu41
 
Importance of clinical trials
Importance of clinical trialsImportance of clinical trials
Importance of clinical trials
SharanyaSreekumar
 

Similar to Effects of dots in HIV infected patients suffering from Tuberculosis (20)

Introduction to Phase 2 & 3 Clinical Trials
Introduction to Phase 2 & 3 Clinical TrialsIntroduction to Phase 2 & 3 Clinical Trials
Introduction to Phase 2 & 3 Clinical Trials
 
Presentation on theme: "GCP (GOOD CLINICAL PRACTISE)"
Presentation on theme: "GCP (GOOD CLINICAL PRACTISE)"Presentation on theme: "GCP (GOOD CLINICAL PRACTISE)"
Presentation on theme: "GCP (GOOD CLINICAL PRACTISE)"
 
clinial trail documentation ppt M pharm pharmacology
clinial trail documentation ppt M pharm pharmacologyclinial trail documentation ppt M pharm pharmacology
clinial trail documentation ppt M pharm pharmacology
 
New Drug Discovery.pptx
New Drug Discovery.pptxNew Drug Discovery.pptx
New Drug Discovery.pptx
 
planning and initiation.pptx
planning and initiation.pptxplanning and initiation.pptx
planning and initiation.pptx
 
Drug trail in cardiology i.tammi raju
Drug trail in cardiology i.tammi rajuDrug trail in cardiology i.tammi raju
Drug trail in cardiology i.tammi raju
 
ROLES AND RESPONSIBLITIES OF CLINICAL TRIAL PERSONNEL-INVESTIGATOR.pptx
ROLES AND RESPONSIBLITIES OF CLINICAL TRIAL PERSONNEL-INVESTIGATOR.pptxROLES AND RESPONSIBLITIES OF CLINICAL TRIAL PERSONNEL-INVESTIGATOR.pptx
ROLES AND RESPONSIBLITIES OF CLINICAL TRIAL PERSONNEL-INVESTIGATOR.pptx
 
Clinical trials
Clinical trialsClinical trials
Clinical trials
 
DEVELOPING CLINICAL TRIAL PROTOCOL BY PRANAV LENDHEY.pptx
DEVELOPING CLINICAL TRIAL PROTOCOL BY PRANAV LENDHEY.pptxDEVELOPING CLINICAL TRIAL PROTOCOL BY PRANAV LENDHEY.pptx
DEVELOPING CLINICAL TRIAL PROTOCOL BY PRANAV LENDHEY.pptx
 
bharat seminar on clinical trial.pptx
bharat  seminar on clinical trial.pptxbharat  seminar on clinical trial.pptx
bharat seminar on clinical trial.pptx
 
Clinical trial study team
Clinical trial study teamClinical trial study team
Clinical trial study team
 
CRO.pptx
CRO.pptxCRO.pptx
CRO.pptx
 
Cinical trial protocol writing
Cinical trial protocol writingCinical trial protocol writing
Cinical trial protocol writing
 
institutional ethics committee
institutional ethics committeeinstitutional ethics committee
institutional ethics committee
 
Preparation of protocol
Preparation of protocolPreparation of protocol
Preparation of protocol
 
Turacoz - Clinical Study Report
Turacoz - Clinical Study ReportTuracoz - Clinical Study Report
Turacoz - Clinical Study Report
 
What is clinical research? Why to do it?
What is clinical research? Why to do it?What is clinical research? Why to do it?
What is clinical research? Why to do it?
 
signaldetectionandmanagement-210803014643.pdf
signaldetectionandmanagement-210803014643.pdfsignaldetectionandmanagement-210803014643.pdf
signaldetectionandmanagement-210803014643.pdf
 
Signal detection and management
Signal detection and managementSignal detection and management
Signal detection and management
 
Importance of clinical trials
Importance of clinical trialsImportance of clinical trials
Importance of clinical trials
 

Recently uploaded

Ophthalmology Clinical Tests for OSCE exam
Ophthalmology Clinical Tests for OSCE examOphthalmology Clinical Tests for OSCE exam
Ophthalmology Clinical Tests for OSCE exam
KafrELShiekh University
 
Surat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model Safe
Surat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model SafeSurat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model Safe
Surat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model Safe
Savita Shen $i11
 
micro teaching on communication m.sc nursing.pdf
micro teaching on communication m.sc nursing.pdfmicro teaching on communication m.sc nursing.pdf
micro teaching on communication m.sc nursing.pdf
Anurag Sharma
 
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stock
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in StockFactory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stock
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stock
rebeccabio
 
Couples presenting to the infertility clinic- Do they really have infertility...
Couples presenting to the infertility clinic- Do they really have infertility...Couples presenting to the infertility clinic- Do they really have infertility...
Couples presenting to the infertility clinic- Do they really have infertility...
Sujoy Dasgupta
 
BENIGN PROSTATIC HYPERPLASIA.BPH. BPHpdf
BENIGN PROSTATIC HYPERPLASIA.BPH. BPHpdfBENIGN PROSTATIC HYPERPLASIA.BPH. BPHpdf
BENIGN PROSTATIC HYPERPLASIA.BPH. BPHpdf
DR SETH JOTHAM
 
Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdf
Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdfAlcohol_Dr. Jeenal Mistry MD Pharmacology.pdf
Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdf
Dr Jeenal Mistry
 
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdf
ARTIFICIAL INTELLIGENCE IN  HEALTHCARE.pdfARTIFICIAL INTELLIGENCE IN  HEALTHCARE.pdf
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdf
Anujkumaranit
 
Prix Galien International 2024 Forum Program
Prix Galien International 2024 Forum ProgramPrix Galien International 2024 Forum Program
Prix Galien International 2024 Forum Program
Levi Shapiro
 
BRACHYTHERAPY OVERVIEW AND APPLICATORS
BRACHYTHERAPY OVERVIEW  AND  APPLICATORSBRACHYTHERAPY OVERVIEW  AND  APPLICATORS
BRACHYTHERAPY OVERVIEW AND APPLICATORS
Krishan Murari
 
The Normal Electrocardiogram - Part I of II
The Normal Electrocardiogram - Part I of IIThe Normal Electrocardiogram - Part I of II
The Normal Electrocardiogram - Part I of II
MedicoseAcademics
 
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptxMaxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Dr. Rabia Inam Gandapore
 
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...
kevinkariuki227
 
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdf
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdfMANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdf
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdf
Jim Jacob Roy
 
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists  Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
Saeid Safari
 
The hemodynamic and autonomic determinants of elevated blood pressure in obes...
The hemodynamic and autonomic determinants of elevated blood pressure in obes...The hemodynamic and autonomic determinants of elevated blood pressure in obes...
The hemodynamic and autonomic determinants of elevated blood pressure in obes...
Catherine Liao
 
Cervical & Brachial Plexus By Dr. RIG.pptx
Cervical & Brachial Plexus By Dr. RIG.pptxCervical & Brachial Plexus By Dr. RIG.pptx
Cervical & Brachial Plexus By Dr. RIG.pptx
Dr. Rabia Inam Gandapore
 
Superficial & Deep Fascia of the NECK.pptx
Superficial & Deep Fascia of the NECK.pptxSuperficial & Deep Fascia of the NECK.pptx
Superficial & Deep Fascia of the NECK.pptx
Dr. Rabia Inam Gandapore
 
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...
Oleg Kshivets
 
Are There Any Natural Remedies To Treat Syphilis.pdf
Are There Any Natural Remedies To Treat Syphilis.pdfAre There Any Natural Remedies To Treat Syphilis.pdf
Are There Any Natural Remedies To Treat Syphilis.pdf
Little Cross Family Clinic
 

Recently uploaded (20)

Ophthalmology Clinical Tests for OSCE exam
Ophthalmology Clinical Tests for OSCE examOphthalmology Clinical Tests for OSCE exam
Ophthalmology Clinical Tests for OSCE exam
 
Surat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model Safe
Surat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model SafeSurat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model Safe
Surat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model Safe
 
micro teaching on communication m.sc nursing.pdf
micro teaching on communication m.sc nursing.pdfmicro teaching on communication m.sc nursing.pdf
micro teaching on communication m.sc nursing.pdf
 
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stock
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in StockFactory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stock
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stock
 
Couples presenting to the infertility clinic- Do they really have infertility...
Couples presenting to the infertility clinic- Do they really have infertility...Couples presenting to the infertility clinic- Do they really have infertility...
Couples presenting to the infertility clinic- Do they really have infertility...
 
BENIGN PROSTATIC HYPERPLASIA.BPH. BPHpdf
BENIGN PROSTATIC HYPERPLASIA.BPH. BPHpdfBENIGN PROSTATIC HYPERPLASIA.BPH. BPHpdf
BENIGN PROSTATIC HYPERPLASIA.BPH. BPHpdf
 
Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdf
Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdfAlcohol_Dr. Jeenal Mistry MD Pharmacology.pdf
Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdf
 
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdf
ARTIFICIAL INTELLIGENCE IN  HEALTHCARE.pdfARTIFICIAL INTELLIGENCE IN  HEALTHCARE.pdf
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdf
 
Prix Galien International 2024 Forum Program
Prix Galien International 2024 Forum ProgramPrix Galien International 2024 Forum Program
Prix Galien International 2024 Forum Program
 
BRACHYTHERAPY OVERVIEW AND APPLICATORS
BRACHYTHERAPY OVERVIEW  AND  APPLICATORSBRACHYTHERAPY OVERVIEW  AND  APPLICATORS
BRACHYTHERAPY OVERVIEW AND APPLICATORS
 
The Normal Electrocardiogram - Part I of II
The Normal Electrocardiogram - Part I of IIThe Normal Electrocardiogram - Part I of II
The Normal Electrocardiogram - Part I of II
 
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptxMaxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
 
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...
 
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdf
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdfMANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdf
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdf
 
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists  Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
 
The hemodynamic and autonomic determinants of elevated blood pressure in obes...
The hemodynamic and autonomic determinants of elevated blood pressure in obes...The hemodynamic and autonomic determinants of elevated blood pressure in obes...
The hemodynamic and autonomic determinants of elevated blood pressure in obes...
 
Cervical & Brachial Plexus By Dr. RIG.pptx
Cervical & Brachial Plexus By Dr. RIG.pptxCervical & Brachial Plexus By Dr. RIG.pptx
Cervical & Brachial Plexus By Dr. RIG.pptx
 
Superficial & Deep Fascia of the NECK.pptx
Superficial & Deep Fascia of the NECK.pptxSuperficial & Deep Fascia of the NECK.pptx
Superficial & Deep Fascia of the NECK.pptx
 
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...
 
Are There Any Natural Remedies To Treat Syphilis.pdf
Are There Any Natural Remedies To Treat Syphilis.pdfAre There Any Natural Remedies To Treat Syphilis.pdf
Are There Any Natural Remedies To Treat Syphilis.pdf
 

Effects of dots in HIV infected patients suffering from Tuberculosis

  • 1. GROUP PROJECT PRESENTATION PRESENTED BY LEARNING GROUP 16 HUMAN WELFARE GROUPS TO COMAPARE THE SAFETY & EFFICACY OF TWO DIFFERENT DOTS REGIMEN IN HIV +ve AND NON HIV PATIENTS, INFECTED WITH TUBERCULOSIS A Multicentre Phase III Open-Label Study
  • 2. PROJECT OBJECTIVE • To conduct market research for selection of potential site and feasibility of carrying out the trial in those sites. • To develop all trial related ethical submission deliverables. • To prepare the budget for carrying out the trial. • To develop SOPs for all trial related activities.
  • 3. TASK DELEGATION NAME OF THE PERSON ROLES RESPONSIBILITIES SUBENDU MUKHERJEE PROJECT MANAGER PROTOCOL, RMP, MEETING AGENDA’S, SYSTEMATIC REVIEW SARAH TAREEN DEPUTY PROJECT MANAGER IB, LITERATURE SEARCH , SYSTEMATIC REVIEW P.SHEELA CLINICAL OPERATION MANAGER CRF, QOL, REGULATORY REQUIREMENTS. PANKAJA GOHAIN ADMINISTRATIVE & OPERATION CO- ORDINATOR ICF, MEDICAL INSURANCE, SITE FEASIBILITY CHECKLIST, RECORDING MINUTES OF MEETING SUNITA KUMARI FINANCIAL PLANNER CONFIDENTIALITY REPORT, RMP,BUDGET, SLIDES A.MADHURI QUALITY CONTROL & QUALITY ASSURANCE MANAGER SOP’s, PRESENTATION DAY CO- ORDINATOR,POSTER.
  • 4. Management plan • Adherence to Team SOP’s • Weekly project team status reports • Summary of tasks completed in the previous week • Summary of tasks scheduled for completion in the next week • Compliance with the communication plan and Delegation plan • Monitoring and tracking individual work • Meeting with sponsors and reporting project progress in periodic basis.
  • 5. PROPOSAL STRATEGY • Detailed literature search was done for selecting appropriate site; sites were to be personally visited. • Sites were to be reviewed via site selection checklist. • Trial related essential documents were to be submitted as per Indian GCP. • Standard cost criteria were to be adopted for the budget. • SOPs were to be developed in accordance with applicable regulatory requirements, sponsor’s demands and company standards.
  • 6. PROJECT SCHEDULE • Gantt Chart • group projectProject1-GANTT CHART.mpp
  • 7. BACKGROUND OF THE PROJECT • In last two years 1.8 million cases of TB have been reported in India. • 2009 figure says, there are 2.5 million people suffering from HIV in India. • 26% of the cause for death in HIV infected patients is due to TB. • No trial in India has been conducted yet. • 95% cases of TB are reported in South India and Maharashtra • Number of deaths per year is next to cancer and cardiac diseases.
  • 8. BENEFITS OF THE STUDY • Will walkout with better health conditions.. • Study will enrich their quality of life • Will be exposed to the best treatment to tackle their health hazards. Individual- wise • Help reduce mortality rate for developing countries like India • Improve the QOL for people suffering with TB Society- wise • This trial can help come up with newer findings for DOTS regimen as only a few trial regarding this therapy have been conducted. Science- wise
  • 11. CRITICAL CONSTRAINTS • No previous experience in such projects • Tasks may take longer time than expected • Absenteeism of group member • Loss of data • Delay in work due to power cuts
  • 12. PROTOCOL • AIM : : COMAPARE THE SAFETY & EFFICACY OF TWO DIFFERENT DOTS REGIMEN IN HIV +ve AND NON HIV PATIENTS, INFECTED WITH TUBERCULOSIS • OBJECTIVE:  PRIMARY: To compare the efficacy parameters of two different DOTS regimen in HIV and non HIV patients, in treating tuberculosis.  SECONDARY : 1. To determine the Frequency of ADR in each group of population 2. To determine the survival rate 3. To assess the quality of life of both the population
  • 13. PROTOCOL CONTD. • Study Design: Phase III, non-randomized, open -label, cross-over assignment, multicentre. • SETTINGS: BANGALORE, PUNE, CHENNAI, COCHIN, PUNE. • SAMPLE : 9 0 0 subjects • STUDY DURATION : 3 Years and 2 months. • Primary Endpoints: Reduction in mycobacterium infection in both groups, i.e., reduction in amount of M.Tuberculli infection in sputum test, pulmonary tapping, chest x-ray • Secondary Endpoints: Number of ADR’s in both the groups will be collected and evaluated; number of deaths in both the groups, periodic scores of WHO HIV tool quality of life questionnaire will be assessed.
  • 14. PROTOCOL CONTD. • Safety Endpoint: Occurrence of any ADR or SAE will be considered as safety endpoint. • INCLUSION CRITERIA for HIV + ve + TB group: i. Confirmed diagnosed HIV infection within last 2 years. ii. Confirmed diagnosed TB infection – TB rapid test or sputum smear +ve for acid fast bacilli in last 2 years. iii. Age > 18 iv. Both gender v. Life expectancy of atleast 6 months. vi. Should comply with all study procedures vii. Should provide voluntary written informed consent. Clinical parameters: Neutrophill count > 0.75 * 109 /L Platelet count > 50 * 109/L Hb > 80g/L CD4 + cells < 200 and > 80
  • 15. PROTOCOL CONTD. EFFICACY ASSESSMENT:  1, 2,3,4th month under both the regimen for both the study groups .  To check reduction in M. tuberculli infection from the baseline score.  Via. Sputum test, pulmonary tapping.  Chest X-ray – to check the reduction in cough.  During follow-up along with the above parameters, survival rate and quality of life by WHO standard HIV-TB tool questionnaire will be assessed. • SAFETY ASSESSMENT: • Routine safety assessment test include various test like, physical examination and vital stats parameters. Clinical lab values of CD4 cell count. Reports of any adverse events throughout the trial of every individual subject will be considered for safety assessment.
  • 17. SYSTEMATIC LITERATURE REVIEW • Comprehensive search of published article was done • Clinical trials using rifampin, pyrazinamide, isoniazid and rifabutin drug as investigational product were selected • Retrospective and prospective studies. • No standard inclusion or exclusion criteria • All possible databases were included- PUBMED, NEJM, BMJ • Keywords used for search: , tuberculosis and HIV, DOTS regimen, treatment outcome with Rifampin, Isoniazid, Pyrazinamide, rifabutin
  • 18. INVESTIGATOR’S BROCHURE • IB was prepared in accordance with the Indian GCP. • IB included all the necessary information about the drugs used in the study: Isoniazid, Rifampin, Rifabutin, Pyrazinamide. • For the above mentioned drugs, along with a brief summary of each drug, the following information was included: • Chemical, Physical and formulation parameters. • Data from nonclinical studies • Data from clinical studies • Post marketing experience of each drug • Summary of data and guidance for the investigator
  • 19. INFORMED CONSENT dOCUMENT • PATIENT INFORMATION SHEET: • Patients were formally invited for the trial • They were informed about all the details of the trial • Information about all the personnel involved in the trial • INFORMED CONSENT FORM: • A document containing all the terms and conditions related to the participation in the trial-to be read and signed and dated by the participant or LAR. • Investigator’s certificate declaring that the informed consent was read and signed by the participant. • ICF for TB in non-HIV final.doc • ICF for TB+HIV final.doc
  • 20. SITE SELECTION CKECKLIST • Market research was done for selecting potential site • Telephonic interview was done with the shortlisted sites • F:SITE SELECTION CHECKLIST.docx
  • 21. CASE REPORT FORM • The following headings included all the necessary information needed to be recorded, as per the requirements of the protocol: • CASE REPORT FORM 2.docx • QOL_Questionnare.docx
  • 22. Risk management plan  Risk to participants right • Fully IC • Failure to protect participants privacy  Risk to participants safety • Hazard of the trial medication • Hazards of study assessment methods  Risk to researchers • Staff competence / experience to carry out responsibilities • Contact with harmful chemicals, substances, equipment or organisms • Trial proceeding without the necessary regulatory approvals
  • 23.  RISKS TO COMPLETION OF THE TRIAL • Study Power & Recruitment • Organisational Complexity • Adequacy of trial management  RISKS TO RELIABILITY OF THE RESULTS • Study result • Completeness and accuracy of assessment / data • Adherence to the protocol  RISKS TO THE ORGANISATION • Impact on clinical services • Liability
  • 24. Trial budget Recurring budget- • staff expenses , travel, food, lab cost = INR 3,49,67000 Non recurring- • Med claim, IEC approval, RA, Recruitment, Site cost , Logistics =INR 892000 Miscellaneous expenses = INR 2,35,000
  • 25. SOPs • SOP • Audit • Participant recruitment • ICD • SAE reporting plan • Trial Master file checklist • Monitoring plan
  • 26. Close out to include a discussion of lessons learnt • To work as a team • Time management • Quality work • Effective communication • Understand the importance of roles and responsibilities • Identify and overcome the constraints